10-Q: Delcath Systems Reports Strong Revenue Growth in Q2 2024 Driven by HEPZATO Launch

Delcath Systems saw a significant increase in revenue in the second quarter of 2024, primarily due to the commercial launch of its HEPZATO KIT in the U.S.

Summary

• Delcath Systems, an interventional oncology company, reported its financial results for the second quarter of 2024.
• The company's total revenue increased significantly to $7.766 million for the three months ended June 30, 2024, compared to $0.495 million for the same period in 2023.
• This increase was primarily driven by the commercial launch of the HEPZATO KIT in the U.S., which contributed $6.570 million in revenue.
• CHEMOSAT sales in Europe also contributed $1.196 million in revenue for the quarter.
• The company's gross profit for the quarter was $6.247 million, compared to $0.345 million in the same period last year.
• Operating expenses totaled $10.159 million, with research and development expenses at $3.394 million and selling, general, and administrative expenses at $6.765 million.
• The company reported a net loss of $13.741 million for the quarter, compared to a net loss of $7.202 million in the same period last year.
• For the six months ended June 30, 2024, total revenue was $10.905 million, compared to $1.092 million in the same period in 2023.
• The net loss for the six months ended June 30, 2024 was $24.852 million, compared to a net loss of $16.202 million in the same period last year.
• The company had cash and cash equivalents of $14.8 million and short-term investments of $5.1 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document shows strong revenue growth due to the launch of HEPZATO, which is a positive sign. However, the company is still operating at a loss and has a going concern warning, which tempers the positive outlook. The need for additional capital raises also adds uncertainty.

Positives

• The company experienced a substantial increase in revenue due to the commercial launch of HEPZATO KIT in the U.S.
• There was also an increase in demand for CHEMOSAT in Europe.
• The company's gross profit improved significantly compared to the same period last year.
• The company has sufficient raw material and component parts for HEPZATO KIT to meet anticipated demand.
• The company has a supply agreement with Synerx Pharma and Mylan Teoranta for melphalan through 2028.

Negatives

• The company reported a net loss of $13.741 million for the quarter and $24.852 million for the six months ended June 30, 2024.
• Operating expenses increased due to activities supporting the commercial launch of HEPZATO.
• The company used $14.0 million of cash in operating activities during the six months ended June 30, 2024.
• The company has a history of operating at a loss and there is no assurance of achieving or maintaining profitability.
• The company has a going concern warning due to uncertainty regarding its ability to maintain sufficient liquidity.

Risks

• The company's future results are subject to substantial risks and uncertainties.
• There is a risk of substantial delays in the activation of additional sites to administer HEPZATO.
• The company may need to raise additional capital, which may not be on favorable terms.
• The company's ability to access existing cash, cash equivalents and investments may be threatened if additional banks and financial institutions enter receivership or become insolvent.
• The company's future liquidity and capital requirements will depend on numerous factors, including the success of commercialization efforts, regulatory approvals, and market developments.

Future Outlook

The company plans to begin one or more studies of HEPZATO KIT to treat other cancers in the liver in late 2024 or early 2025. The company expects that the publication of additional data from the Phase 3 FOCUS Trial will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States.

Management Comments

• The company intends to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• The company believes that HEPZATO has the potential to treat other cancers in the liver, such as metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic breast cancer and intrahepatic cholangiocarcinoma.

Industry Context

The company operates in the interventional oncology space, focusing on liver-directed cancer treatments. The approval and commercial launch of HEPZATO KIT is a significant milestone for the company and positions it to compete in the market for liver cancer treatments. The company is also working to expand the use of its products to other cancers in the liver.

Comparison to Industry Standards

• Delcath's revenue growth in Q2 2024 is a positive sign, especially when compared to the previous year's figures, indicating a successful commercial launch of HEPZATO.
• However, the company's continued net losses are a concern, and it will need to demonstrate a path to profitability to be competitive with established pharmaceutical and medical device companies.
• The company's focus on orphan drug designations and specific cancer types is a common strategy for smaller biotech companies to gain market share.
• The company's reliance on external funding through equity and debt offerings is typical for companies in this stage of development, but it also carries risks.
• The company's clinical trial results for HEPZATO, with an Overall Response Rate (ORR) of 36.35%, are promising and could be a competitive advantage compared to other treatments for metastatic uveal melanoma.

Legal Proceedings

• The company has a settlement agreement with medac GmbH regarding a dispute over a License, Supply and Marketing Agreement.

Stakeholder Impact

• Shareholders may be impacted by the company's need to raise additional capital and the potential for dilution.
• Employees may be impacted by the company's financial performance and future growth plans.
• Customers (hospitals and treatment centers) will be impacted by the availability and pricing of HEPZATO and CHEMOSAT.
• Suppliers will be impacted by the company's purchasing decisions and supply chain management.
• Creditors may be impacted by the company's ability to repay its debts.

Next Steps

• The company plans to begin one or more studies of HEPZATO KIT to treat other cancers in the liver in late 2024 or early 2025.
• The company will continue to commercialize HEPZATO and CHEMOSAT.
• The company will seek additional regulatory approvals for HEPZATO and CHEMOSAT in additional jurisdictions and for additional indications.

Key Dates

Keywords

HEPZATO KIT, CHEMOSAT, Uveal Melanoma, Interventional Oncology, Melphalan, Liver Cancer, FDA Approval, Commercial Launch, Revenue Growth, Clinical Trials